Drug intelligence / Profile preview

oncoxin-viusid + docetaxel

Development stage
Unknown
Lead developer
Laboratorios Catalysis
Modality
Small Molecules
Administration
Oral (Oncoxin-Viusid), Intravenous (docetaxel)
01

Overview

Oncoxin-Viusid + docetaxel is a combination therapy consisting of **Oncoxin-Viusid**, a nutritional supplement with antioxidant, immunomodulatory, and anti-tumor properties, and **docetaxel**, a cytotoxic chemotherapeutic agent. Oncoxin-Viusid contains active ingredients such as epigallocatechin gallate (from green tea extract), glycine, glucosamine, arginine, cystine, malic acid, monoammonium glycyrrhizinate, ascorbic acid, zinc sulfate, pyridoxine, folic acid, and cyanocobalamin. Mechanistically, Oncoxin-Viusid acts via antioxidant and anti-proliferative mechanisms, modulation of apoptosis pathways (restoring cellular apoptosis by inducing p53, caspase-3, and BAX expression, while inhibiting anti-apoptotic Bcl-2), inhibition of tumor-promoting enzymes, and immunomodulation (stimulating interferon and IL-12 production, macrophage activation, T-helper cell stimulation). Docetaxel is a classic microtubule inhibitor that promotes apoptosis in cancer cells. The combination is primarily investigated as an adjunct therapy to improve the efficacy and tolerability of docetaxel-based chemotherapy, especially in prostate cancer and other solid tumors, where Oncoxin-Viusid is studied as an adjuvant to reduce toxicity and potentially enhance anti-tumor effects.

Other names
Ocoxin
02

Targets

TNFA (Tumor necrosis factor alpha (soluble))MMP9 (Matrix metalloproteinase-9)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TUBB (Tubulin (alpha and beta subunits))BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)MMP2 (Matrix metalloproteinase-2)PLAU (uPA)

Beyond the preview

Go deeper on oncoxin-viusid + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oncoxin-viusid + docetaxel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call